News

Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...
Researchers developed an AI-powered ECG model, EchoNext, that detects structural heart disease with high accuracy across ...
Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...
The US Food and Drug Administration (FDA) has granted 510(k) clearance for Tempus AI’s ECG-Low (ejection fraction) EF ...
The new Tempus software analyzes resting, non-ambulatory 12-lead ECG recordings to detect signs associated with having a low ...
Researchers at the German Center for Cardiovascular Research (DZHK) have identified a key molecule involved in a form of ...
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...
The era of predictive modeling enhanced with machine learning and artificial intelligence (AI) to aid clinical ...
Medically reviewed by Christopher Lee, MDSystolic congestive heart failure, or systolic heart failure, is a type of heart ...
The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.
Q: Can you tell me about ejection fractions? My wife’s heart doctor recently told us that her heart is weak, and she has a low ejection fraction. He did not discuss this much, but he has put her ...
The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.